Back to top

Silence Therapeutics reports Q2 EPS (9c), consensus (17c)

Cash and cash equivalents were $72.1 million as of June 30, 2026. Pre-clinical pipeline updates: Generated additional preclinical data demonstratin...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Silence Therapeutics PLC Sponsored ADR (SLN)